Payload Information
General Information of This Payload
| Payload ID | PAY0THITY |
|||||
|---|---|---|---|---|---|---|
| Name | MLN8237 |
|||||
| Synonyms |
MLN8237; Alisertib
Click to Show/Hide
|
|||||
| Target | Aurora kinase A (AURKA) | |||||
| Formula | C27H20ClFN4O4 |
|||||
| Isosmiles | COC1=CC(NC2=NC3=C(CN=C(C4=C(F)C=CC=C4OC)C5=C3C=CC(Cl)=C5)C=N2)=CC=C1C(O)=O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
|
|||||
| InChIKey |
ZLHFILGSQDJULK-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
518.932 |
Polar area |
105.93 |
||
Complexity |
1526.166082 |
xlogp Value |
5.7461 |
|||
Heavy Count |
37 |
Rot Bonds |
6 |
|||
Hbond acc |
7 |
Hbond Donor |
2 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.14 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.14 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.23 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.23 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -1.282 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -107.25 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -11.77 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -13 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -14 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -17 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -3 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -3.032 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -39 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -64 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | -7.522 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -79 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -9 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -9 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | -9.458 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -97 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | 0 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.8165 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 10.02 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 10.94 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell Viability (%) | 103.39 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 113.91 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 116.53 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 117.66 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 120.56 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 13 | % |
HEK-293T cells
|
Normal
|
||
| Cell Viability (%) | 13.71 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 14.5 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 16.14 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 16.25 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 16.37 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 16.65 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 168.73 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 169.32 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 19 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Percent Inhibition (%) | 19.5 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 19.72 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 19.91 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 2.31 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 20.05 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 21.7 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 24.63 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 25 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Growth Rate | 26 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 26.16 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 26.21 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 286.42 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 29.16 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 3 | % |
HEK-293T cells
|
Normal
|
||
| Cell Viability (%) | 32.9 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 322.75 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 322.75 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 33 | % |
HEK-293T cells
|
Normal
|
||
| Cell Viability (%) | 34.52 | % | Undisclosed | Undisclosed | Undisclosed | |
| Maximum Effect (Emax) | 37 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | 38 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | 39 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | 39 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 4.436 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 41 | % |
U2OS cells
|
Osteosarcoma
|
||
| Tumor Growth Inhibition (TGI) | 42 | % |
MM1.S cells
|
Plasma cell myeloma, Multiple myeloma
|
||
| Cell-based Growth Rate | 43 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | 45 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell Viability (%) | 46.57 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 47.68 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 54 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cellular activity | 54.2 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell Viability (%) | 6.089 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 6.089 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 65 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | 68 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell Viability (%) | 7.3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 7.435 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 71.99 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 76.21 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 77.2 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell Viability (%) | 8.923 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 80 | % |
MM1.S cells
|
Plasma cell myeloma, Multiple myeloma
|
||
| Cell Viability (%) | 81.61 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 83 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Percent Inhibition (%) | >90 | % |
NCI-H82 cells
|
Lung small cell carcinoma
|
||
| Cell Viability (%) | 97.73 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell Viability (%) | 99.74 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.04 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
NCI-H358 cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
MRC5 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1097.5 | nM |
U-266 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 12500 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 12500 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.3 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
MIA PaCa-2 cells
|
Pancreatic undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 133.5 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OCI-LY19 cells
|
Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1533.7 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
PC-14 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 320 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 32000 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39 | nM |
GSS cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 396 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 396 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 396.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 396.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 40.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 431 | nM |
SW480 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 490 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 500 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 502.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 54 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.7 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.7 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 62 | nM |
LU-99A cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 74 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 740 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 77 | nM |
LC-2-ad cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 93 | nM |
MKN-45 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 95 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 97 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
38751786 5D3 (CC-MLB8237)3.2-AF488 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
8.17 nM
|
Negative PSMA expression (PSMA-) | ||
| Method Description |
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | PC3-PIP cells | CVCL_E9XK | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
161.9 nM
|
Positive PSMA expression (PSMA+++/++) | ||
| Method Description |
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | PC3-Flu cells | Homo sapiens | ||
References
